The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.
The final, formatted version of the article will be published soon. 1 Background: Sintilimab plus a Bevacizumab biosimilar (IBI305) is an approved first-line 2 regimen for unresectable hepatocellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback